ClinicalTrials.gg
CompletedNCT04418609Neuro-COVIDUpdated Aug 4, 2022

Neuro-COVID-19: Neurological Complications of COVID-19

An observational study in Neurologic Complication, sponsored by Emanuela Keller. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-04.

Sponsored by Emanuela Keller · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
8
Ages
18 Years and older
Sex
All
01

Study summary

The prevalence and typical patterns of neurological complications in hospitalized COVID-19 patients admitted to the intensive care units of the University Hospital Zurich will be investigated. The impact of neurological complications among COVID-19 patients on mortality, functional outcome, and organizational outcomes will be analyzed.

Read the detailed description

This study is a prospective observational cohort study to document prevalence and severity of neurological symptoms among patients requiring critical care admission for confirmed novel coronavirus disease (COVID-19). COVID-19 is classified as severe acute respiratory syndrome 2 (SARS-CoV-2) and shares significant structural and biological similarities with SARS-CoV, which has neuroinvasive properties and brainstem involvement. Early reports of COVID-19 progression indicate presence of severe neurological complications, including seizures, coma, encephalitis, and cerebrovascular events including ischemic stroke, intracranial hemorrhage, and cerebral venous sinus thromboses. In addition, recent data from Zika-virus and H1N1 influenza pandemics reveal a high incidence of neurological complications, including Guillain Barré syndrome and neonatal microcephaly for Zika-virus and narcolepsy with H1N1 infections. Early reports from China suggest neurological symptoms may occur in approximately 36% of SARS-CoV-2 positive patients, with increased prevalence among more severe cases, and fall into three categories: central nervous system symptoms or diseases, peripheral nervous system symptoms, and skeletal muscular symptoms. However, the exact prevalence of these conditions and impact on patient disease severity and outcomes is unknown. As the incidence and severity of COVID-19 infection continues to rapidly rise on an international level, it is imperative to capture prospective data to accurately document prevalence, severity and clinical characterization of neurological components of COVID-19, the influence of treatment regimens of neurological complications, and role of these confounders on patient and organizational outcomes.

02

Conditions studied

  • Neurologic Complication
03

In context

Lead sponsor

Emanuela Keller is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients admitted to the Intensive Care Units (ICUs) of the Institute of Intensive Care Medicine, University Hospital of Zurich meeting eligibility criteria during the pandemic will be enrolled.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (age > 18 years old) treated at ICUs
  • Admitted with confirmed COVID-19 infection
  • Patient exhibiting acute neurological manifestations
  • General consent of the Institute of Intensive Care Medicine available from patient or legal representative

Exclusion criteria

Exclusion Criteria:

  • Pre-existing severe neurologic dysfunction
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
8 participants (actual)
Patient registry
No

Interventions

  • Otherfurther processing of health data

    further processing of biological materials and health related personal data for research

    Also known as: further processing of biological materials and health related personal data

06

What researchers measure

Primary outcomes

  1. Prevalence of neurological complications

    Determine the prevalence of neurological complications in hospitalized COVID-19 patients admitted to the intensive care unit.

    Time frame: through study completion, on an average of 3 weeks

  2. Prevalence and outcome of severe neurological complications

    Examine if empiric COVID-19 therapies are associated with difference in the prevalence and outcome of severe neurological complications of COVID-19.

    Time frame: through study completion, on an average of 3 weeks

  3. Impact of neurological complications

    Determine the impact of neurological complications among COVID-19 patients on mortality, functional outcome, and organizational outcomes (ICU length of stay, hospital length of stay) among patients with confirmed COVID-19.

    Time frame: through study completion, on an average of 3 weeks

  4. Characteristic patterns in cerebral imaging and electroencephalography (EEG), as well as cerebrospinal fluid (CSF)

    Analyze characteristic patterns in cerebral imaging and electroencephalography (EEG), as well as cerebrospinal fluid (CSF) of patients, in whom a lumbar puncture has been performed for clinical reasons

    Time frame: through study completion, on an average of 3 weeks

  5. Brain for pathological changes and histopathological findings (if patient dies).

    Analyze the brain for pathological changes and histopathological findings, if the patient dies.

    Time frame: through study completion, on an average of 3 weeks

07

Study locations

1 site
  • University Hospital Zurich
    Zürich, 8091, Switzerland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2020 to primary completion in Jun 2022, 25 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2020
First posted
Jun 5, 2020
StartActual
May 1, 2020
Primary completionActual
Jun 9, 2022
CompletionActual
Jun 9, 2022
Last update
Aug 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04418609
Lead sponsor
Emanuela Keller
Responsible party
Emanuela Keller (Prof. Dr. Emanuela Keller, University of Zurich) — Sponsor-investigator
First posted
Jun 5, 2020
Start date
May 1, 2020
Primary completion
Jun 9, 2022
Completion
Jun 9, 2022
Last update
Aug 4, 2022

Study contacts

Emanuela Keller, Prof. Dr.
principal investigator · University Hospital, Zürich

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion